Geographic Region 1
Country A: Drug X B: Placebo C: Combination All Patients
Investigator Identifier (N=134) (N=134) (N=132) (N=400)
—————————————————————————————————————————————————————————————————————————————————————
Africa 8 (6.0%) 7 (5.2%) 11 (8.3%) 26 (6.5%)
NGA 8 (6.0%) 7 (5.2%) 11 (8.3%) 26 (6.5%)
INV ID NGA-1 3 (37.5%) 3 (42.9%) 4 (36.4%) 10 (38.5%)
INV ID NGA-11 1 (12.5%) 2 (28.6%) 3 (27.3%) 6 (23.1%)
INV ID NGA-12 0 1 (14.3%) 1 (9.1%) 2 (7.7%)
INV ID NGA-17 2 (25%) 0 0 2 (7.7%)
INV ID NGA-2 1 (12.5%) 1 (14.3%) 0 2 (7.7%)
INV ID NGA-4 1 (12.5%) 0 1 (9.1%) 2 (7.7%)
INV ID NGA-5 0 0 1 (9.1%) 1 (3.8%)
INV ID NGA-6 0 0 1 (9.1%) 1 (3.8%)
Asia 91 (67.9%) 94 (70.1%) 83 (62.9%) 268 (67.0%)
CHN 74 (55.2%) 81 (60.4%) 64 (48.5%) 219 (54.8%)
INV ID CHN-1 21 (28.4%) 20 (24.7%) 16 (25%) 57 (26%)
INV ID CHN-10 0 1 (1.2%) 0 1 (0.5%)
INV ID CHN-11 12 (16.2%) 20 (24.7%) 16 (25%) 48 (21.9%)
INV ID CHN-12 4 (5.4%) 3 (3.7%) 1 (1.6%) 8 (3.7%)
INV ID CHN-13 2 (2.7%) 6 (7.4%) 0 8 (3.7%)
INV ID CHN-14 4 (5.4%) 2 (2.5%) 3 (4.7%) 9 (4.1%)
INV ID CHN-15 2 (2.7%) 0 4 (6.2%) 6 (2.7%)
INV ID CHN-16 0 3 (3.7%) 3 (4.7%) 6 (2.7%)
INV ID CHN-17 4 (5.4%) 4 (4.9%) 3 (4.7%) 11 (5%)
INV ID CHN-18 1 (1.4%) 0 2 (3.1%) 3 (1.4%)
INV ID CHN-2 9 (12.2%) 4 (4.9%) 3 (4.7%) 16 (7.3%)
INV ID CHN-3 5 (6.8%) 1 (1.2%) 5 (7.8%) 11 (5%)
INV ID CHN-4 3 (4.1%) 3 (3.7%) 3 (4.7%) 9 (4.1%)
INV ID CHN-5 4 (5.4%) 3 (3.7%) 4 (6.2%) 11 (5%)
INV ID CHN-6 1 (1.4%) 3 (3.7%) 0 4 (1.8%)
INV ID CHN-7 0 5 (6.2%) 1 (1.6%) 6 (2.7%)
INV ID CHN-8 1 (1.4%) 1 (1.2%) 0 2 (0.9%)
INV ID CHN-9 1 (1.4%) 2 (2.5%) 0 3 (1.4%)
PAK 12 (9.0%) 9 (6.7%) 10 (7.6%) 31 (7.8%)
INV ID PAK-1 2 (16.7%) 4 (44.4%) 4 (40%) 10 (32.3%)
INV ID PAK-11 4 (33.3%) 3 (33.3%) 2 (20%) 9 (29%)
INV ID PAK-12 2 (16.7%) 0 0 2 (6.5%)
INV ID PAK-13 1 (8.3%) 1 (11.1%) 0 2 (6.5%)
INV ID PAK-14 1 (8.3%) 0 0 1 (3.2%)
INV ID PAK-15 1 (8.3%) 0 0 1 (3.2%)
INV ID PAK-2 1 (8.3%) 0 2 (20%) 3 (9.7%)
INV ID PAK-4 0 1 (11.1%) 1 (10%) 2 (6.5%)
INV ID PAK-5 0 0 1 (10%) 1 (3.2%)
JPN 5 (3.7%) 4 (3.0%) 9 (6.8%) 18 (4.5%)
INV ID JPN-1 2 (40%) 2 (50%) 1 (11.1%) 5 (27.8%)
INV ID JPN-11 0 0 3 (33.3%) 3 (16.7%)
INV ID JPN-12 0 0 1 (11.1%) 1 (5.6%)
INV ID JPN-14 0 1 (25%) 0 1 (5.6%)
INV ID JPN-17 0 0 2 (22.2%) 2 (11.1%)
INV ID JPN-18 1 (20%) 0 0 1 (5.6%)
INV ID JPN-2 0 0 1 (11.1%) 1 (5.6%)
INV ID JPN-3 0 1 (25%) 0 1 (5.6%)
INV ID JPN-5 1 (20%) 0 1 (11.1%) 2 (11.1%)
INV ID JPN-6 1 (20%) 0 0 1 (5.6%)
Eurasia 5 (3.7%) 8 (6.0%) 6 (4.5%) 19 (4.8%)
RUS 5 (3.7%) 8 (6.0%) 6 (4.5%) 19 (4.8%)
INV ID RUS-1 1 (20%) 0 0 1 (5.3%)
INV ID RUS-11 0 2 (25%) 2 (33.3%) 4 (21.1%)
INV ID RUS-12 0 1 (12.5%) 0 1 (5.3%)
INV ID RUS-13 1 (20%) 0 0 1 (5.3%)
INV ID RUS-14 0 0 1 (16.7%) 1 (5.3%)
INV ID RUS-16 1 (20%) 1 (12.5%) 0 2 (10.5%)
INV ID RUS-18 1 (20%) 0 0 1 (5.3%)
INV ID RUS-2 0 1 (12.5%) 0 1 (5.3%)
INV ID RUS-3 0 0 1 (16.7%) 1 (5.3%)
INV ID RUS-4 0 2 (25%) 1 (16.7%) 3 (15.8%)
INV ID RUS-5 0 1 (12.5%) 0 1 (5.3%)
INV ID RUS-6 1 (20%) 0 0 1 (5.3%)
INV ID RUS-7 0 0 1 (16.7%) 1 (5.3%)
Europe 4 (3.0%) 3 (2.2%) 2 (1.5%) 9 (2.2%)
GBR 4 (3.0%) 3 (2.2%) 2 (1.5%) 9 (2.2%)
INV ID GBR-1 2 (50%) 0 1 (50%) 3 (33.3%)
INV ID GBR-11 0 1 (33.3%) 1 (50%) 2 (22.2%)
INV ID GBR-13 1 (25%) 0 0 1 (11.1%)
INV ID GBR-15 1 (25%) 0 0 1 (11.1%)
INV ID GBR-17 0 1 (33.3%) 0 1 (11.1%)
INV ID GBR-6 0 1 (33.3%) 0 1 (11.1%)
North America 13 (9.7%) 15 (11.2%) 20 (15.2%) 48 (12.0%)
USA 10 (7.5%) 13 (9.7%) 17 (12.9%) 40 (10.0%)
INV ID USA-1 1 (10%) 4 (30.8%) 5 (29.4%) 10 (25%)
INV ID USA-11 4 (40%) 2 (15.4%) 3 (17.6%) 9 (22.5%)
INV ID USA-12 1 (10%) 2 (15.4%) 3 (17.6%) 6 (15%)
INV ID USA-14 1 (10%) 0 0 1 (2.5%)
INV ID USA-15 0 1 (7.7%) 1 (5.9%) 2 (5%)
INV ID USA-17 1 (10%) 1 (7.7%) 0 2 (5%)
INV ID USA-19 0 0 1 (5.9%) 1 (2.5%)
INV ID USA-2 0 0 1 (5.9%) 1 (2.5%)
INV ID USA-3 1 (10%) 0 1 (5.9%) 2 (5%)
INV ID USA-4 0 1 (7.7%) 1 (5.9%) 2 (5%)
INV ID USA-5 0 1 (7.7%) 0 1 (2.5%)
INV ID USA-6 0 1 (7.7%) 0 1 (2.5%)
INV ID USA-8 0 0 1 (5.9%) 1 (2.5%)
INV ID USA-9 1 (10%) 0 0 1 (2.5%)
CAN 3 (2.2%) 2 (1.5%) 3 (2.3%) 8 (2.0%)
INV ID CAN-1 1 (33.3%) 1 (50%) 0 2 (25%)
INV ID CAN-11 1 (33.3%) 0 1 (33.3%) 2 (25%)
INV ID CAN-14 1 (33.3%) 0 0 1 (12.5%)
INV ID CAN-4 0 1 (50%) 1 (33.3%) 2 (25%)
INV ID CAN-5 0 0 1 (33.3%) 1 (12.5%)
South America 13 (9.7%) 7 (5.2%) 10 (7.6%) 30 (7.5%)
BRA 13 (9.7%) 7 (5.2%) 10 (7.6%) 30 (7.5%)
INV ID BRA-1 4 (30.8%) 2 (28.6%) 2 (20%) 8 (26.7%)
INV ID BRA-11 4 (30.8%) 0 4 (40%) 8 (26.7%)
INV ID BRA-12 0 1 (14.3%) 0 1 (3.3%)
INV ID BRA-13 1 (7.7%) 0 0 1 (3.3%)
INV ID BRA-14 1 (7.7%) 0 1 (10%) 2 (6.7%)
INV ID BRA-15 1 (7.7%) 0 0 1 (3.3%)
INV ID BRA-2 1 (7.7%) 1 (14.3%) 0 2 (6.7%)
INV ID BRA-3 0 2 (28.6%) 0 2 (6.7%)
INV ID BRA-4 0 1 (14.3%) 1 (10%) 2 (6.7%)
INV ID BRA-5 0 0 1 (10%) 1 (3.3%)
INV ID BRA-6 1 (7.7%) 0 0 1 (3.3%)
INV ID BRA-7 0 0 1 (10%) 1 (3.3%)
Experimental use!
WebR is a tool allowing you to run R code in the web browser. Modify the code below and click run to see the results. Alternatively, copy the code and click here to open WebR in a new tab.
Country A: Drug X B: Placebo C: Combination All Patients
Investigator Identifier (N=134) (N=134) (N=132) (N=400)
———————————————————————————————————————————————————————————————————————————————————
CHN 74 (55.2%) 81 (60.4%) 64 (48.5%) 219 (54.8%)
INV ID CHN-1 21 (28.4%) 20 (24.7%) 16 (25%) 57 (26%)
INV ID CHN-10 0 1 (1.2%) 0 1 (0.5%)
INV ID CHN-11 12 (16.2%) 20 (24.7%) 16 (25%) 48 (21.9%)
INV ID CHN-12 4 (5.4%) 3 (3.7%) 1 (1.6%) 8 (3.7%)
INV ID CHN-13 2 (2.7%) 6 (7.4%) 0 8 (3.7%)
INV ID CHN-14 4 (5.4%) 2 (2.5%) 3 (4.7%) 9 (4.1%)
INV ID CHN-15 2 (2.7%) 0 4 (6.2%) 6 (2.7%)
INV ID CHN-16 0 3 (3.7%) 3 (4.7%) 6 (2.7%)
INV ID CHN-17 4 (5.4%) 4 (4.9%) 3 (4.7%) 11 (5%)
INV ID CHN-18 1 (1.4%) 0 2 (3.1%) 3 (1.4%)
INV ID CHN-2 9 (12.2%) 4 (4.9%) 3 (4.7%) 16 (7.3%)
INV ID CHN-3 5 (6.8%) 1 (1.2%) 5 (7.8%) 11 (5%)
INV ID CHN-4 3 (4.1%) 3 (3.7%) 3 (4.7%) 9 (4.1%)
INV ID CHN-5 4 (5.4%) 3 (3.7%) 4 (6.2%) 11 (5%)
INV ID CHN-6 1 (1.4%) 3 (3.7%) 0 4 (1.8%)
INV ID CHN-7 0 5 (6.2%) 1 (1.6%) 6 (2.7%)
INV ID CHN-8 1 (1.4%) 1 (1.2%) 0 2 (0.9%)
INV ID CHN-9 1 (1.4%) 2 (2.5%) 0 3 (1.4%)
USA 10 (7.5%) 13 (9.7%) 17 (12.9%) 40 (10.0%)
INV ID USA-1 1 (10%) 4 (30.8%) 5 (29.4%) 10 (25%)
INV ID USA-11 4 (40%) 2 (15.4%) 3 (17.6%) 9 (22.5%)
INV ID USA-12 1 (10%) 2 (15.4%) 3 (17.6%) 6 (15%)
INV ID USA-14 1 (10%) 0 0 1 (2.5%)
INV ID USA-15 0 1 (7.7%) 1 (5.9%) 2 (5%)
INV ID USA-17 1 (10%) 1 (7.7%) 0 2 (5%)
INV ID USA-19 0 0 1 (5.9%) 1 (2.5%)
INV ID USA-2 0 0 1 (5.9%) 1 (2.5%)
INV ID USA-3 1 (10%) 0 1 (5.9%) 2 (5%)
INV ID USA-4 0 1 (7.7%) 1 (5.9%) 2 (5%)
INV ID USA-5 0 1 (7.7%) 0 1 (2.5%)
INV ID USA-6 0 1 (7.7%) 0 1 (2.5%)
INV ID USA-8 0 0 1 (5.9%) 1 (2.5%)
INV ID USA-9 1 (10%) 0 0 1 (2.5%)
BRA 13 (9.7%) 7 (5.2%) 10 (7.6%) 30 (7.5%)
INV ID BRA-1 4 (30.8%) 2 (28.6%) 2 (20%) 8 (26.7%)
INV ID BRA-11 4 (30.8%) 0 4 (40%) 8 (26.7%)
INV ID BRA-12 0 1 (14.3%) 0 1 (3.3%)
INV ID BRA-13 1 (7.7%) 0 0 1 (3.3%)
INV ID BRA-14 1 (7.7%) 0 1 (10%) 2 (6.7%)
INV ID BRA-15 1 (7.7%) 0 0 1 (3.3%)
INV ID BRA-2 1 (7.7%) 1 (14.3%) 0 2 (6.7%)
INV ID BRA-3 0 2 (28.6%) 0 2 (6.7%)
INV ID BRA-4 0 1 (14.3%) 1 (10%) 2 (6.7%)
INV ID BRA-5 0 0 1 (10%) 1 (3.3%)
INV ID BRA-6 1 (7.7%) 0 0 1 (3.3%)
INV ID BRA-7 0 0 1 (10%) 1 (3.3%)
PAK 12 (9.0%) 9 (6.7%) 10 (7.6%) 31 (7.8%)
INV ID PAK-1 2 (16.7%) 4 (44.4%) 4 (40%) 10 (32.3%)
INV ID PAK-11 4 (33.3%) 3 (33.3%) 2 (20%) 9 (29%)
INV ID PAK-12 2 (16.7%) 0 0 2 (6.5%)
INV ID PAK-13 1 (8.3%) 1 (11.1%) 0 2 (6.5%)
INV ID PAK-14 1 (8.3%) 0 0 1 (3.2%)
INV ID PAK-15 1 (8.3%) 0 0 1 (3.2%)
INV ID PAK-2 1 (8.3%) 0 2 (20%) 3 (9.7%)
INV ID PAK-4 0 1 (11.1%) 1 (10%) 2 (6.5%)
INV ID PAK-5 0 0 1 (10%) 1 (3.2%)
NGA 8 (6.0%) 7 (5.2%) 11 (8.3%) 26 (6.5%)
INV ID NGA-1 3 (37.5%) 3 (42.9%) 4 (36.4%) 10 (38.5%)
INV ID NGA-11 1 (12.5%) 2 (28.6%) 3 (27.3%) 6 (23.1%)
INV ID NGA-12 0 1 (14.3%) 1 (9.1%) 2 (7.7%)
INV ID NGA-17 2 (25%) 0 0 2 (7.7%)
INV ID NGA-2 1 (12.5%) 1 (14.3%) 0 2 (7.7%)
INV ID NGA-4 1 (12.5%) 0 1 (9.1%) 2 (7.7%)
INV ID NGA-5 0 0 1 (9.1%) 1 (3.8%)
INV ID NGA-6 0 0 1 (9.1%) 1 (3.8%)
RUS 5 (3.7%) 8 (6.0%) 6 (4.5%) 19 (4.8%)
INV ID RUS-1 1 (20%) 0 0 1 (5.3%)
INV ID RUS-11 0 2 (25%) 2 (33.3%) 4 (21.1%)
INV ID RUS-12 0 1 (12.5%) 0 1 (5.3%)
INV ID RUS-13 1 (20%) 0 0 1 (5.3%)
INV ID RUS-14 0 0 1 (16.7%) 1 (5.3%)
INV ID RUS-16 1 (20%) 1 (12.5%) 0 2 (10.5%)
INV ID RUS-18 1 (20%) 0 0 1 (5.3%)
INV ID RUS-2 0 1 (12.5%) 0 1 (5.3%)
INV ID RUS-3 0 0 1 (16.7%) 1 (5.3%)
INV ID RUS-4 0 2 (25%) 1 (16.7%) 3 (15.8%)
INV ID RUS-5 0 1 (12.5%) 0 1 (5.3%)
INV ID RUS-6 1 (20%) 0 0 1 (5.3%)
INV ID RUS-7 0 0 1 (16.7%) 1 (5.3%)
JPN 5 (3.7%) 4 (3.0%) 9 (6.8%) 18 (4.5%)
INV ID JPN-1 2 (40%) 2 (50%) 1 (11.1%) 5 (27.8%)
INV ID JPN-11 0 0 3 (33.3%) 3 (16.7%)
INV ID JPN-12 0 0 1 (11.1%) 1 (5.6%)
INV ID JPN-14 0 1 (25%) 0 1 (5.6%)
INV ID JPN-17 0 0 2 (22.2%) 2 (11.1%)
INV ID JPN-18 1 (20%) 0 0 1 (5.6%)
INV ID JPN-2 0 0 1 (11.1%) 1 (5.6%)
INV ID JPN-3 0 1 (25%) 0 1 (5.6%)
INV ID JPN-5 1 (20%) 0 1 (11.1%) 2 (11.1%)
INV ID JPN-6 1 (20%) 0 0 1 (5.6%)
GBR 4 (3.0%) 3 (2.2%) 2 (1.5%) 9 (2.2%)
INV ID GBR-1 2 (50%) 0 1 (50%) 3 (33.3%)
INV ID GBR-11 0 1 (33.3%) 1 (50%) 2 (22.2%)
INV ID GBR-13 1 (25%) 0 0 1 (11.1%)
INV ID GBR-15 1 (25%) 0 0 1 (11.1%)
INV ID GBR-17 0 1 (33.3%) 0 1 (11.1%)
INV ID GBR-6 0 1 (33.3%) 0 1 (11.1%)
CAN 3 (2.2%) 2 (1.5%) 3 (2.3%) 8 (2.0%)
INV ID CAN-1 1 (33.3%) 1 (50%) 0 2 (25%)
INV ID CAN-11 1 (33.3%) 0 1 (33.3%) 2 (25%)
INV ID CAN-14 1 (33.3%) 0 0 1 (12.5%)
INV ID CAN-4 0 1 (50%) 1 (33.3%) 2 (25%)
INV ID CAN-5 0 0 1 (33.3%) 1 (12.5%)
Experimental use!
WebR is a tool allowing you to run R code in the web browser. Modify the code below and click run to see the results. Alternatively, copy the code and click here to open WebR in a new tab.
Geographic Region 1
Country A: Drug X B: Placebo C: Combination All Patients
Investigator Number/Name (N=134) (N=134) (N=132) (N=400)
————————————————————————————————————————————————————————————————————————————————————————————
Africa 8 (6.0%) 7 (5.2%) 11 (8.3%) 26 (6.5%)
NGA 8 (6.0%) 7 (5.2%) 11 (8.3%) 26 (6.5%)
INV ID NGA-1 / Dr. NGA-1 Doe 3 (37.5%) 3 (42.9%) 4 (36.4%) 10 (38.5%)
INV ID NGA-11 / Dr. NGA-11 Doe 1 (12.5%) 2 (28.6%) 3 (27.3%) 6 (23.1%)
INV ID NGA-12 / Dr. NGA-12 Doe 0 1 (14.3%) 1 (9.1%) 2 (7.7%)
INV ID NGA-17 / Dr. NGA-17 Doe 2 (25%) 0 0 2 (7.7%)
INV ID NGA-2 / Dr. NGA-2 Doe 1 (12.5%) 1 (14.3%) 0 2 (7.7%)
INV ID NGA-4 / Dr. NGA-4 Doe 1 (12.5%) 0 1 (9.1%) 2 (7.7%)
INV ID NGA-5 / Dr. NGA-5 Doe 0 0 1 (9.1%) 1 (3.8%)
INV ID NGA-6 / Dr. NGA-6 Doe 0 0 1 (9.1%) 1 (3.8%)
Asia 91 (67.9%) 94 (70.1%) 83 (62.9%) 268 (67.0%)
CHN 74 (55.2%) 81 (60.4%) 64 (48.5%) 219 (54.8%)
INV ID CHN-1 / Dr. CHN-1 Doe 21 (28.4%) 20 (24.7%) 16 (25%) 57 (26%)
INV ID CHN-10 / Dr. CHN-10 Doe 0 1 (1.2%) 0 1 (0.5%)
INV ID CHN-11 / Dr. CHN-11 Doe 12 (16.2%) 20 (24.7%) 16 (25%) 48 (21.9%)
INV ID CHN-12 / Dr. CHN-12 Doe 4 (5.4%) 3 (3.7%) 1 (1.6%) 8 (3.7%)
INV ID CHN-13 / Dr. CHN-13 Doe 2 (2.7%) 6 (7.4%) 0 8 (3.7%)
INV ID CHN-14 / Dr. CHN-14 Doe 4 (5.4%) 2 (2.5%) 3 (4.7%) 9 (4.1%)
INV ID CHN-15 / Dr. CHN-15 Doe 2 (2.7%) 0 4 (6.2%) 6 (2.7%)
INV ID CHN-16 / Dr. CHN-16 Doe 0 3 (3.7%) 3 (4.7%) 6 (2.7%)
INV ID CHN-17 / Dr. CHN-17 Doe 4 (5.4%) 4 (4.9%) 3 (4.7%) 11 (5%)
INV ID CHN-18 / Dr. CHN-18 Doe 1 (1.4%) 0 2 (3.1%) 3 (1.4%)
INV ID CHN-2 / Dr. CHN-2 Doe 9 (12.2%) 4 (4.9%) 3 (4.7%) 16 (7.3%)
INV ID CHN-3 / Dr. CHN-3 Doe 5 (6.8%) 1 (1.2%) 5 (7.8%) 11 (5%)
INV ID CHN-4 / Dr. CHN-4 Doe 3 (4.1%) 3 (3.7%) 3 (4.7%) 9 (4.1%)
INV ID CHN-5 / Dr. CHN-5 Doe 4 (5.4%) 3 (3.7%) 4 (6.2%) 11 (5%)
INV ID CHN-6 / Dr. CHN-6 Doe 1 (1.4%) 3 (3.7%) 0 4 (1.8%)
INV ID CHN-7 / Dr. CHN-7 Doe 0 5 (6.2%) 1 (1.6%) 6 (2.7%)
INV ID CHN-8 / Dr. CHN-8 Doe 1 (1.4%) 1 (1.2%) 0 2 (0.9%)
INV ID CHN-9 / Dr. CHN-9 Doe 1 (1.4%) 2 (2.5%) 0 3 (1.4%)
PAK 12 (9.0%) 9 (6.7%) 10 (7.6%) 31 (7.8%)
INV ID PAK-1 / Dr. PAK-1 Doe 2 (16.7%) 4 (44.4%) 4 (40%) 10 (32.3%)
INV ID PAK-11 / Dr. PAK-11 Doe 4 (33.3%) 3 (33.3%) 2 (20%) 9 (29%)
INV ID PAK-12 / Dr. PAK-12 Doe 2 (16.7%) 0 0 2 (6.5%)
INV ID PAK-13 / Dr. PAK-13 Doe 1 (8.3%) 1 (11.1%) 0 2 (6.5%)
INV ID PAK-14 / Dr. PAK-14 Doe 1 (8.3%) 0 0 1 (3.2%)
INV ID PAK-15 / Dr. PAK-15 Doe 1 (8.3%) 0 0 1 (3.2%)
INV ID PAK-2 / Dr. PAK-2 Doe 1 (8.3%) 0 2 (20%) 3 (9.7%)
INV ID PAK-4 / Dr. PAK-4 Doe 0 1 (11.1%) 1 (10%) 2 (6.5%)
INV ID PAK-5 / Dr. PAK-5 Doe 0 0 1 (10%) 1 (3.2%)
JPN 5 (3.7%) 4 (3.0%) 9 (6.8%) 18 (4.5%)
INV ID JPN-1 / Dr. JPN-1 Doe 2 (40%) 2 (50%) 1 (11.1%) 5 (27.8%)
INV ID JPN-11 / Dr. JPN-11 Doe 0 0 3 (33.3%) 3 (16.7%)
INV ID JPN-12 / Dr. JPN-12 Doe 0 0 1 (11.1%) 1 (5.6%)
INV ID JPN-14 / Dr. JPN-14 Doe 0 1 (25%) 0 1 (5.6%)
INV ID JPN-17 / Dr. JPN-17 Doe 0 0 2 (22.2%) 2 (11.1%)
INV ID JPN-18 / Dr. JPN-18 Doe 1 (20%) 0 0 1 (5.6%)
INV ID JPN-2 / Dr. JPN-2 Doe 0 0 1 (11.1%) 1 (5.6%)
INV ID JPN-3 / Dr. JPN-3 Doe 0 1 (25%) 0 1 (5.6%)
INV ID JPN-5 / Dr. JPN-5 Doe 1 (20%) 0 1 (11.1%) 2 (11.1%)
INV ID JPN-6 / Dr. JPN-6 Doe 1 (20%) 0 0 1 (5.6%)
Eurasia 5 (3.7%) 8 (6.0%) 6 (4.5%) 19 (4.8%)
RUS 5 (3.7%) 8 (6.0%) 6 (4.5%) 19 (4.8%)
INV ID RUS-1 / Dr. RUS-1 Doe 1 (20%) 0 0 1 (5.3%)
INV ID RUS-11 / Dr. RUS-11 Doe 0 2 (25%) 2 (33.3%) 4 (21.1%)
INV ID RUS-12 / Dr. RUS-12 Doe 0 1 (12.5%) 0 1 (5.3%)
INV ID RUS-13 / Dr. RUS-13 Doe 1 (20%) 0 0 1 (5.3%)
INV ID RUS-14 / Dr. RUS-14 Doe 0 0 1 (16.7%) 1 (5.3%)
INV ID RUS-16 / Dr. RUS-16 Doe 1 (20%) 1 (12.5%) 0 2 (10.5%)
INV ID RUS-18 / Dr. RUS-18 Doe 1 (20%) 0 0 1 (5.3%)
INV ID RUS-2 / Dr. RUS-2 Doe 0 1 (12.5%) 0 1 (5.3%)
INV ID RUS-3 / Dr. RUS-3 Doe 0 0 1 (16.7%) 1 (5.3%)
INV ID RUS-4 / Dr. RUS-4 Doe 0 2 (25%) 1 (16.7%) 3 (15.8%)
INV ID RUS-5 / Dr. RUS-5 Doe 0 1 (12.5%) 0 1 (5.3%)
INV ID RUS-6 / Dr. RUS-6 Doe 1 (20%) 0 0 1 (5.3%)
INV ID RUS-7 / Dr. RUS-7 Doe 0 0 1 (16.7%) 1 (5.3%)
Europe 4 (3.0%) 3 (2.2%) 2 (1.5%) 9 (2.2%)
GBR 4 (3.0%) 3 (2.2%) 2 (1.5%) 9 (2.2%)
INV ID GBR-1 / Dr. GBR-1 Doe 2 (50%) 0 1 (50%) 3 (33.3%)
INV ID GBR-11 / Dr. GBR-11 Doe 0 1 (33.3%) 1 (50%) 2 (22.2%)
INV ID GBR-13 / Dr. GBR-13 Doe 1 (25%) 0 0 1 (11.1%)
INV ID GBR-15 / Dr. GBR-15 Doe 1 (25%) 0 0 1 (11.1%)
INV ID GBR-17 / Dr. GBR-17 Doe 0 1 (33.3%) 0 1 (11.1%)
INV ID GBR-6 / Dr. GBR-6 Doe 0 1 (33.3%) 0 1 (11.1%)
North America 13 (9.7%) 15 (11.2%) 20 (15.2%) 48 (12.0%)
USA 10 (7.5%) 13 (9.7%) 17 (12.9%) 40 (10.0%)
INV ID USA-1 / Dr. USA-1 Doe 1 (10%) 4 (30.8%) 5 (29.4%) 10 (25%)
INV ID USA-11 / Dr. USA-11 Doe 4 (40%) 2 (15.4%) 3 (17.6%) 9 (22.5%)
INV ID USA-12 / Dr. USA-12 Doe 1 (10%) 2 (15.4%) 3 (17.6%) 6 (15%)
INV ID USA-14 / Dr. USA-14 Doe 1 (10%) 0 0 1 (2.5%)
INV ID USA-15 / Dr. USA-15 Doe 0 1 (7.7%) 1 (5.9%) 2 (5%)
INV ID USA-17 / Dr. USA-17 Doe 1 (10%) 1 (7.7%) 0 2 (5%)
INV ID USA-19 / Dr. USA-19 Doe 0 0 1 (5.9%) 1 (2.5%)
INV ID USA-2 / Dr. USA-2 Doe 0 0 1 (5.9%) 1 (2.5%)
INV ID USA-3 / Dr. USA-3 Doe 1 (10%) 0 1 (5.9%) 2 (5%)
INV ID USA-4 / Dr. USA-4 Doe 0 1 (7.7%) 1 (5.9%) 2 (5%)
INV ID USA-5 / Dr. USA-5 Doe 0 1 (7.7%) 0 1 (2.5%)
INV ID USA-6 / Dr. USA-6 Doe 0 1 (7.7%) 0 1 (2.5%)
INV ID USA-8 / Dr. USA-8 Doe 0 0 1 (5.9%) 1 (2.5%)
INV ID USA-9 / Dr. USA-9 Doe 1 (10%) 0 0 1 (2.5%)
CAN 3 (2.2%) 2 (1.5%) 3 (2.3%) 8 (2.0%)
INV ID CAN-1 / Dr. CAN-1 Doe 1 (33.3%) 1 (50%) 0 2 (25%)
INV ID CAN-11 / Dr. CAN-11 Doe 1 (33.3%) 0 1 (33.3%) 2 (25%)
INV ID CAN-14 / Dr. CAN-14 Doe 1 (33.3%) 0 0 1 (12.5%)
INV ID CAN-4 / Dr. CAN-4 Doe 0 1 (50%) 1 (33.3%) 2 (25%)
INV ID CAN-5 / Dr. CAN-5 Doe 0 0 1 (33.3%) 1 (12.5%)
South America 13 (9.7%) 7 (5.2%) 10 (7.6%) 30 (7.5%)
BRA 13 (9.7%) 7 (5.2%) 10 (7.6%) 30 (7.5%)
INV ID BRA-1 / Dr. BRA-1 Doe 4 (30.8%) 2 (28.6%) 2 (20%) 8 (26.7%)
INV ID BRA-11 / Dr. BRA-11 Doe 4 (30.8%) 0 4 (40%) 8 (26.7%)
INV ID BRA-12 / Dr. BRA-12 Doe 0 1 (14.3%) 0 1 (3.3%)
INV ID BRA-13 / Dr. BRA-13 Doe 1 (7.7%) 0 0 1 (3.3%)
INV ID BRA-14 / Dr. BRA-14 Doe 1 (7.7%) 0 1 (10%) 2 (6.7%)
INV ID BRA-15 / Dr. BRA-15 Doe 1 (7.7%) 0 0 1 (3.3%)
INV ID BRA-2 / Dr. BRA-2 Doe 1 (7.7%) 1 (14.3%) 0 2 (6.7%)
INV ID BRA-3 / Dr. BRA-3 Doe 0 2 (28.6%) 0 2 (6.7%)
INV ID BRA-4 / Dr. BRA-4 Doe 0 1 (14.3%) 1 (10%) 2 (6.7%)
INV ID BRA-5 / Dr. BRA-5 Doe 0 0 1 (10%) 1 (3.3%)
INV ID BRA-6 / Dr. BRA-6 Doe 1 (7.7%) 0 0 1 (3.3%)
INV ID BRA-7 / Dr. BRA-7 Doe 0 0 1 (10%) 1 (3.3%)
Experimental use!
WebR is a tool allowing you to run R code in the web browser. Modify the code below and click run to see the results. Alternatively, copy the code and click here to open WebR in a new tab.
Country A: Drug X B: Placebo C: Combination All Patients
Investigator Number/Name (N=134) (N=134) (N=132) (N=400)
——————————————————————————————————————————————————————————————————————————————————————————
CHN 74 (55.2%) 81 (60.4%) 64 (48.5%) 219 (54.8%)
INV ID CHN-1 / Dr. CHN-1 Doe 21 (28.4%) 20 (24.7%) 16 (25%) 57 (26%)
INV ID CHN-10 / Dr. CHN-10 Doe 0 1 (1.2%) 0 1 (0.5%)
INV ID CHN-11 / Dr. CHN-11 Doe 12 (16.2%) 20 (24.7%) 16 (25%) 48 (21.9%)
INV ID CHN-12 / Dr. CHN-12 Doe 4 (5.4%) 3 (3.7%) 1 (1.6%) 8 (3.7%)
INV ID CHN-13 / Dr. CHN-13 Doe 2 (2.7%) 6 (7.4%) 0 8 (3.7%)
INV ID CHN-14 / Dr. CHN-14 Doe 4 (5.4%) 2 (2.5%) 3 (4.7%) 9 (4.1%)
INV ID CHN-15 / Dr. CHN-15 Doe 2 (2.7%) 0 4 (6.2%) 6 (2.7%)
INV ID CHN-16 / Dr. CHN-16 Doe 0 3 (3.7%) 3 (4.7%) 6 (2.7%)
INV ID CHN-17 / Dr. CHN-17 Doe 4 (5.4%) 4 (4.9%) 3 (4.7%) 11 (5%)
INV ID CHN-18 / Dr. CHN-18 Doe 1 (1.4%) 0 2 (3.1%) 3 (1.4%)
INV ID CHN-2 / Dr. CHN-2 Doe 9 (12.2%) 4 (4.9%) 3 (4.7%) 16 (7.3%)
INV ID CHN-3 / Dr. CHN-3 Doe 5 (6.8%) 1 (1.2%) 5 (7.8%) 11 (5%)
INV ID CHN-4 / Dr. CHN-4 Doe 3 (4.1%) 3 (3.7%) 3 (4.7%) 9 (4.1%)
INV ID CHN-5 / Dr. CHN-5 Doe 4 (5.4%) 3 (3.7%) 4 (6.2%) 11 (5%)
INV ID CHN-6 / Dr. CHN-6 Doe 1 (1.4%) 3 (3.7%) 0 4 (1.8%)
INV ID CHN-7 / Dr. CHN-7 Doe 0 5 (6.2%) 1 (1.6%) 6 (2.7%)
INV ID CHN-8 / Dr. CHN-8 Doe 1 (1.4%) 1 (1.2%) 0 2 (0.9%)
INV ID CHN-9 / Dr. CHN-9 Doe 1 (1.4%) 2 (2.5%) 0 3 (1.4%)
USA 10 (7.5%) 13 (9.7%) 17 (12.9%) 40 (10.0%)
INV ID USA-1 / Dr. USA-1 Doe 1 (10%) 4 (30.8%) 5 (29.4%) 10 (25%)
INV ID USA-11 / Dr. USA-11 Doe 4 (40%) 2 (15.4%) 3 (17.6%) 9 (22.5%)
INV ID USA-12 / Dr. USA-12 Doe 1 (10%) 2 (15.4%) 3 (17.6%) 6 (15%)
INV ID USA-14 / Dr. USA-14 Doe 1 (10%) 0 0 1 (2.5%)
INV ID USA-15 / Dr. USA-15 Doe 0 1 (7.7%) 1 (5.9%) 2 (5%)
INV ID USA-17 / Dr. USA-17 Doe 1 (10%) 1 (7.7%) 0 2 (5%)
INV ID USA-19 / Dr. USA-19 Doe 0 0 1 (5.9%) 1 (2.5%)
INV ID USA-2 / Dr. USA-2 Doe 0 0 1 (5.9%) 1 (2.5%)
INV ID USA-3 / Dr. USA-3 Doe 1 (10%) 0 1 (5.9%) 2 (5%)
INV ID USA-4 / Dr. USA-4 Doe 0 1 (7.7%) 1 (5.9%) 2 (5%)
INV ID USA-5 / Dr. USA-5 Doe 0 1 (7.7%) 0 1 (2.5%)
INV ID USA-6 / Dr. USA-6 Doe 0 1 (7.7%) 0 1 (2.5%)
INV ID USA-8 / Dr. USA-8 Doe 0 0 1 (5.9%) 1 (2.5%)
INV ID USA-9 / Dr. USA-9 Doe 1 (10%) 0 0 1 (2.5%)
BRA 13 (9.7%) 7 (5.2%) 10 (7.6%) 30 (7.5%)
INV ID BRA-1 / Dr. BRA-1 Doe 4 (30.8%) 2 (28.6%) 2 (20%) 8 (26.7%)
INV ID BRA-11 / Dr. BRA-11 Doe 4 (30.8%) 0 4 (40%) 8 (26.7%)
INV ID BRA-12 / Dr. BRA-12 Doe 0 1 (14.3%) 0 1 (3.3%)
INV ID BRA-13 / Dr. BRA-13 Doe 1 (7.7%) 0 0 1 (3.3%)
INV ID BRA-14 / Dr. BRA-14 Doe 1 (7.7%) 0 1 (10%) 2 (6.7%)
INV ID BRA-15 / Dr. BRA-15 Doe 1 (7.7%) 0 0 1 (3.3%)
INV ID BRA-2 / Dr. BRA-2 Doe 1 (7.7%) 1 (14.3%) 0 2 (6.7%)
INV ID BRA-3 / Dr. BRA-3 Doe 0 2 (28.6%) 0 2 (6.7%)
INV ID BRA-4 / Dr. BRA-4 Doe 0 1 (14.3%) 1 (10%) 2 (6.7%)
INV ID BRA-5 / Dr. BRA-5 Doe 0 0 1 (10%) 1 (3.3%)
INV ID BRA-6 / Dr. BRA-6 Doe 1 (7.7%) 0 0 1 (3.3%)
INV ID BRA-7 / Dr. BRA-7 Doe 0 0 1 (10%) 1 (3.3%)
PAK 12 (9.0%) 9 (6.7%) 10 (7.6%) 31 (7.8%)
INV ID PAK-1 / Dr. PAK-1 Doe 2 (16.7%) 4 (44.4%) 4 (40%) 10 (32.3%)
INV ID PAK-11 / Dr. PAK-11 Doe 4 (33.3%) 3 (33.3%) 2 (20%) 9 (29%)
INV ID PAK-12 / Dr. PAK-12 Doe 2 (16.7%) 0 0 2 (6.5%)
INV ID PAK-13 / Dr. PAK-13 Doe 1 (8.3%) 1 (11.1%) 0 2 (6.5%)
INV ID PAK-14 / Dr. PAK-14 Doe 1 (8.3%) 0 0 1 (3.2%)
INV ID PAK-15 / Dr. PAK-15 Doe 1 (8.3%) 0 0 1 (3.2%)
INV ID PAK-2 / Dr. PAK-2 Doe 1 (8.3%) 0 2 (20%) 3 (9.7%)
INV ID PAK-4 / Dr. PAK-4 Doe 0 1 (11.1%) 1 (10%) 2 (6.5%)
INV ID PAK-5 / Dr. PAK-5 Doe 0 0 1 (10%) 1 (3.2%)
NGA 8 (6.0%) 7 (5.2%) 11 (8.3%) 26 (6.5%)
INV ID NGA-1 / Dr. NGA-1 Doe 3 (37.5%) 3 (42.9%) 4 (36.4%) 10 (38.5%)
INV ID NGA-11 / Dr. NGA-11 Doe 1 (12.5%) 2 (28.6%) 3 (27.3%) 6 (23.1%)
INV ID NGA-12 / Dr. NGA-12 Doe 0 1 (14.3%) 1 (9.1%) 2 (7.7%)
INV ID NGA-17 / Dr. NGA-17 Doe 2 (25%) 0 0 2 (7.7%)
INV ID NGA-2 / Dr. NGA-2 Doe 1 (12.5%) 1 (14.3%) 0 2 (7.7%)
INV ID NGA-4 / Dr. NGA-4 Doe 1 (12.5%) 0 1 (9.1%) 2 (7.7%)
INV ID NGA-5 / Dr. NGA-5 Doe 0 0 1 (9.1%) 1 (3.8%)
INV ID NGA-6 / Dr. NGA-6 Doe 0 0 1 (9.1%) 1 (3.8%)
RUS 5 (3.7%) 8 (6.0%) 6 (4.5%) 19 (4.8%)
INV ID RUS-1 / Dr. RUS-1 Doe 1 (20%) 0 0 1 (5.3%)
INV ID RUS-11 / Dr. RUS-11 Doe 0 2 (25%) 2 (33.3%) 4 (21.1%)
INV ID RUS-12 / Dr. RUS-12 Doe 0 1 (12.5%) 0 1 (5.3%)
INV ID RUS-13 / Dr. RUS-13 Doe 1 (20%) 0 0 1 (5.3%)
INV ID RUS-14 / Dr. RUS-14 Doe 0 0 1 (16.7%) 1 (5.3%)
INV ID RUS-16 / Dr. RUS-16 Doe 1 (20%) 1 (12.5%) 0 2 (10.5%)
INV ID RUS-18 / Dr. RUS-18 Doe 1 (20%) 0 0 1 (5.3%)
INV ID RUS-2 / Dr. RUS-2 Doe 0 1 (12.5%) 0 1 (5.3%)
INV ID RUS-3 / Dr. RUS-3 Doe 0 0 1 (16.7%) 1 (5.3%)
INV ID RUS-4 / Dr. RUS-4 Doe 0 2 (25%) 1 (16.7%) 3 (15.8%)
INV ID RUS-5 / Dr. RUS-5 Doe 0 1 (12.5%) 0 1 (5.3%)
INV ID RUS-6 / Dr. RUS-6 Doe 1 (20%) 0 0 1 (5.3%)
INV ID RUS-7 / Dr. RUS-7 Doe 0 0 1 (16.7%) 1 (5.3%)
JPN 5 (3.7%) 4 (3.0%) 9 (6.8%) 18 (4.5%)
INV ID JPN-1 / Dr. JPN-1 Doe 2 (40%) 2 (50%) 1 (11.1%) 5 (27.8%)
INV ID JPN-11 / Dr. JPN-11 Doe 0 0 3 (33.3%) 3 (16.7%)
INV ID JPN-12 / Dr. JPN-12 Doe 0 0 1 (11.1%) 1 (5.6%)
INV ID JPN-14 / Dr. JPN-14 Doe 0 1 (25%) 0 1 (5.6%)
INV ID JPN-17 / Dr. JPN-17 Doe 0 0 2 (22.2%) 2 (11.1%)
INV ID JPN-18 / Dr. JPN-18 Doe 1 (20%) 0 0 1 (5.6%)
INV ID JPN-2 / Dr. JPN-2 Doe 0 0 1 (11.1%) 1 (5.6%)
INV ID JPN-3 / Dr. JPN-3 Doe 0 1 (25%) 0 1 (5.6%)
INV ID JPN-5 / Dr. JPN-5 Doe 1 (20%) 0 1 (11.1%) 2 (11.1%)
INV ID JPN-6 / Dr. JPN-6 Doe 1 (20%) 0 0 1 (5.6%)
GBR 4 (3.0%) 3 (2.2%) 2 (1.5%) 9 (2.2%)
INV ID GBR-1 / Dr. GBR-1 Doe 2 (50%) 0 1 (50%) 3 (33.3%)
INV ID GBR-11 / Dr. GBR-11 Doe 0 1 (33.3%) 1 (50%) 2 (22.2%)
INV ID GBR-13 / Dr. GBR-13 Doe 1 (25%) 0 0 1 (11.1%)
INV ID GBR-15 / Dr. GBR-15 Doe 1 (25%) 0 0 1 (11.1%)
INV ID GBR-17 / Dr. GBR-17 Doe 0 1 (33.3%) 0 1 (11.1%)
INV ID GBR-6 / Dr. GBR-6 Doe 0 1 (33.3%) 0 1 (11.1%)
CAN 3 (2.2%) 2 (1.5%) 3 (2.3%) 8 (2.0%)
INV ID CAN-1 / Dr. CAN-1 Doe 1 (33.3%) 1 (50%) 0 2 (25%)
INV ID CAN-11 / Dr. CAN-11 Doe 1 (33.3%) 0 1 (33.3%) 2 (25%)
INV ID CAN-14 / Dr. CAN-14 Doe 1 (33.3%) 0 0 1 (12.5%)
INV ID CAN-4 / Dr. CAN-4 Doe 0 1 (50%) 1 (33.3%) 2 (25%)
INV ID CAN-5 / Dr. CAN-5 Doe 0 0 1 (33.3%) 1 (12.5%)
Experimental use!
WebR is a tool allowing you to run R code in the web browser. Modify the code below and click run to see the results. Alternatively, copy the code and click here to open WebR in a new tab.
Code
library(dplyr)library(forcats)library(tern)adsl <- random.cdisc.data::cadsl# Ensure character variables are converted to factors and empty strings and NAs are explicit missing levels.adsl <-df_explicit_na(adsl)adsl <- adsl %>%mutate(REGION1 =droplevels(REGION1),COUNTRY =droplevels(COUNTRY),INVID_INVNAM =paste(INVID, INVNAM, sep =" / ") ) %>%mutate(INVID =factor(INVID),SITEID =factor(SITEID),INVNAM =factor(INVNAM),INVID_INVNAM =factor(INVID_INVNAM) ) %>%var_relabel(INVID_INVNAM ="Investigator Number/Name",REGION1 ="Geographic Region 1",COUNTRY ="Country",INVID ="Investigator Identifier" ) %>%arrange(REGION1, COUNTRY, INVID)
Note that for this module application, only the variables passed into by_vars are used when row_groups is selected. Variables passed into analyze_vars are additionally used when row_groups is deselected.
shinylive allow you to modify to run shiny application entirely in the web browser. Modify the code below and click re-run the app to see the results. The performance is slighly worse and some of the features (e.g. downloading) might not work at all.